India Pharma Outlook Team | Monday, 07 September 2026
Chronic care and GLP-1 therapeutics reshape the Indian Pharmaceutical Market as demand shifts decisively toward long-term therapies.
Lifestyle diseases drive sticky revenues while acute care faces margin pressure. Indian drugmakers actively chase cardiovascular, oncology, and anti-diabetes portfolios.
GLP-1 molecules open a new metabolic goldmine as global patents loosen. Alongside these developments, government funding through Biopharma SHAKTI accelerates complex biologics.
Investors weigh high valuations against concentrated therapeutic risks. This transition marks a fundamental change in how the IPM grows, competes, and creates value through 2030.
India’s pharmaceutical market stands at approximately USD 55–60 billion today and targets USD 130 billion by 2030. Commerce and Industry Minister Jitin Prasada confirms this trajectory, positioning the sector as a global cost-effective healthcare destination.
Historically, anti-infectives and pain management dominated volumes with thin margins. Anti-infectives still held 34.11 per cent market share in 2025, yet growth slows under stewardship programs.
Chronic therapies now deliver higher and more predictable margins. Patients with diabetes, cardiovascular disease, and cancer require multi-year treatment, creating recurring revenue streams.
Rapid chronic-disease incidence expands long-term demand, lifting anti-diabetic, statin, and antihypertensive volumes by double digits annually. This structural move from volume-driven acute care to value-driven chronic care underpins the market’s projected expansion.
Key growth drivers include:
Lifestyle diseases surge across India. Cardiovascular disease cases reached 64 million in 2024, while diabetes affected 89.8 million adults, with projections climbing toward 156.7 million by 2050. These numbers expand the addressable market for long-term therapies.
Oncology leads growth with an 8.22 per cent CAGR through 2031 as biosimilars gain traction under state cancer schemes. Cardiovascular therapies already account for roughly 22 per cent of revenue, supported by fixed-dose combinations that improve adherence.
Similarly, anti-diabetic therapeutics serve more than 100 million patients and continue to post strong double-digit volume gains. For example, Cipla’s chronic-care revenue grew 19 per cent in fiscal 2025, outpacing its acute portfolio.
These three segments together pull the IPM away from episodic prescribing toward continuous therapy management, delivering both higher content per patient and greater revenue visibility for manufacturers.
Also Read: How Biologics and Complex Therapies Are Reshaping CDMO Strategy
GLP-1 receptor agonists and dual agonists transform diabetes and obesity treatment. Molecules such as semaglutide and tirzepatide deliver clinically proven HbA1c reduction alongside 10–15 per cent or higher body-weight loss. Tirzepatide’s dual GLP-1 mechanism sets new efficacy benchmarks, while oral candidates like orforglipron and danuglipron promise broader accessibility.
Indian majors actively prepare domestic manufacturing, licensing, and generic development as global patents begin to open. This sub-segment shifts consumer healthcare spend from traditional anti-diabetics toward higher-value metabolic therapies.
Patients and physicians increasingly view GLP-1 drugs as foundational rather than niche options, creating a multi-year revenue opportunity for companies that secure early formulation and scale capabilities.
The Union Budget 2026-27 launches Biopharma SHAKTI with Rs 10,000 crore outlay over five years. The scheme builds an end-to-end ecosystem for biologics, biosimilars, and advanced therapies.
It establishes three new NIPERs, upgrades seven existing ones, creates more than 1,000 accredited clinical trial sites, and strengthens CDSCO with specialized scientific cadres.
Biopharma SHAKTI incentivizes a decisive move away from copycat molecules toward complex biologics that address non-communicable diseases. Industry leaders describe this initiative as a game-changer that positions India for value-driven global leadership in high-value chronic therapies.
High valuations in the pharma space reflect optimism around chronic and metabolic growth, yet concentrated exposure to specific therapy portfolios carries risk. Expanded price-control mechanisms under the National List of Essential Medicines can compress margins on widely used chronic drugs. Clinical-trial delays or regulatory setbacks in complex biologics can also slow pipeline realization.
Companies that diversify across cardiovascular, oncology, anti-diabetes, and emerging GLP-1 platforms while maintaining operational excellence stand better positioned. Those over-reliant on a narrow set of molecules remain vulnerable to policy shifts or competitive intensity. Balanced portfolios and disciplined capital allocation therefore remain essential as the IPM completes its transition to chronic-care leadership.
Chronic care and GLP-1 therapeutics are fundamentally reshaping the Indian Pharmaceutical Market. The shift from low-margin acute therapies to high-value, recurring chronic treatments driven by rising lifestyle diseases underpins the sector’s projected growth to USD 130 billion by 2030.
Cardiovascular, oncology, and anti-diabetes segments already deliver stronger volumes and visibility, while GLP-1 molecules open a powerful new metabolic opportunity as patents ease.
Government support through the Rs 10,000-crore Biopharma SHAKTI scheme accelerates the move into complex biologics and biosimilars, strengthening India’s position in high-value therapies. For investors, the transition offers clear upside but requires careful navigation of valuation levels, price control risks, and portfolio concentration.
Companies that build diversified chronic and metabolic portfolios, invest in manufacturing scale, and maintain operational discipline stand best placed to capture the next phase of growth. The IPM’s future lies in long-term therapy management, innovation, and sustained patient demand rather than episodic acute care.
.jpg)
